Please login to the form below

Not currently logged in
Email:
Password:

XLMTM

This page shows the latest XLMTM news and features for those working in and with pharma, biotech and healthcare.

Audentes’ rare disease gene therapy programme delayed after third patient death

Audentes’ rare disease gene therapy programme delayed after third patient death

AT132 is an aden-associated virus (AAV) based gene therapy that is designed to deliver the MTM1 gene deficient in XLMTM.

Latest news

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have...
Clinical trials and the diversity principle
If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue....
marketing satnav
Mapping at launch: it’s time to update the satnav
How mapping familiar basics can provide a new GPS for market access strategy that drives brand success...

Infographics